Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +55.31% Revenue per Share is $0.03 as of Jun. 2026. The stock has 1 warning sign investors should review. Among 191 Medical Diagnostics & Research companies, Invitro International ranks worse than 85.34% on this metric.
Invitro International's revenue per share for the
three
months ended in Jun. 2026 was $0.01.
Invitro International's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.03.
Warning Sign:
Invitro International revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Invitro International was -8.10% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -25.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -34.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Invitro International's Revenue per Share or its related term are showing as below:
IVRO'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -38.6 Med: -29.45 Max: 3.4
Current: -25
During the past 9 years, Invitro International's highest 3-Year average Revenue Per Share Growth Rate was 3.40% per year. The lowest was -38.60% per year. And the median was -29.45% per year.
IVRO's 3-Year Revenue Growth Rate is ranked worse than 85.34% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.2
vs IVRO: -25.00
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Invitro International Revenue per Share Related Terms
Invitro International Revenue per Share Historical Data
* Premium members only.
The historical data trend for Invitro International's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVRO vs IDTA, PRPH, NSTM: Revenue per Share Comparison
For the Diagnostics & Research subindustry, Invitro International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's PS Ratio distribution charts can be found below:
* The bar in red indicates where Invitro International's PS Ratio falls into.
Invitro International Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Invitro International's Revenue Per Share for the fiscal year that ended in Sep. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a Revenue per Share of $0.03 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Invitro International and its competitors. According to the industry distribution chart, Invitro International ranks #163 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 85.3%.
Is Invitro International's Revenue per Share too high?
Invitro International's current Revenue per Share is $0.03. The Medical Diagnostics & Research industry median Revenue per Share is 1.20. Invitro International's value of $0.03 is 97.5% below this industry median. Based on the distribution chart, Invitro International ranks #163 out of 191 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Invitro International's Revenue per Share compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #163 out of 191 companies for Revenue per Share. This places Invitro International in the lower half of its industry. The industry median Revenue per Share is 1.20. Invitro International's value of $0.03 is 97.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Diagnostics & Research company?
The median Revenue per Share among Medical Diagnostics & Research companies is 1.20, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current Revenue per Share of $0.03 is 97.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median Revenue per Share is 1.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current Revenue per Share is $0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.06, compared to a current price of $0.08 — trading 26.8% above its estimated fair value. The current Revenue per Share is $0.03 and 97.5% below the Medical Diagnostics & Research industry median of 1.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Invitro International (IVRO), the current Revenue per Share is $0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
